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Abstract
Background: Vitamin D deficiency and insufficiency have been established to be strongly associated with increased
overall mortality and deaths from specific aging-related diseases. Recently, an epigenetic “mortality risk score” (MS)
based on whole blood DNA methylation at the 10 most prominent mortality-related cytosine-phosphate-guanine
(CpG) sites has also been found to be highly related to all-cause mortality. This study aimed to explore whether vitamin
D status, defined by serum 25-hydroxyvitamin D [25(OH)D] concentrations, is associated with the MS and to what
extent both indicators are individually and jointly capable of predicting all-cause mortality in a general population
sample of older adults.
Results: The MS was derived from the blood DNA methylation profiles measured by Illumina Human Methylation 450K
Beadchip, and serum 25(OH)D concentration was measured among 1467 participants aged 50–75 of the German
ESTHER cohort study. There was no association between vitamin D status and the MS at baseline, but both metrics
were prominently and independently associated with all-cause mortality during a median follow-up of 15.2 years.
The combination of both indicators showed the potential to be a particularly strong prognostic index for all-cause
mortality. Participants with vitamin D deficiency (< 30 nmol/L) and high MS (> 5 CpG sites with aberrant methylation)
had almost sixfold mortality (hazard ratio 5.79, 95% CI 3.06–10.94) compared with participants with sufficient vitamin D
(≥ 50 nmol/L) and a low MS (0–1 CpG site with aberrant methylation).
Conclusions: This study suggests that vitamin D and the MS are strong independent predictors of all-cause mortality
in older adults.
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Precision medicine
Background
Vitamin D is a critical nutrient that is, apart from some
limited supply from diet and supplement use, mainly
obtained from the biosynthesis within the human body in
response to the exposure of solar ultraviolet B radiation
[1]. Vitamin D status is commonly measured via assessing
25-hydroxyvitamin D [25(OH)D] concentrations in serum
[1]. Vitamin D deficiency and insufficiency have been
shown to be strongly associated with increased overall
mortality, as well as deaths from specific aging-related
diseases, such as cardiovascular disease (CVD) and various
forms of cancer [2–4]. We previously performed a
meta-analysis to summarize the results of eight prospect-
ive cohort studies from European countries and the USA
to investigate the prognostic association of vitamin D sta-
tus and mortality [3]. Comparing bottom vs. top quintiles
of 25(OH)D concentrations resulted in a risk ratio of 1.57
(95% CI 1.36–1.81) for all-cause mortality.
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Recently, DNA methylation, one of the most studied
and stable epigenetic modifications, has been shown to
be associated with aging and aging-related health
outcomes [5, 6] and recognized as the indicator for
all-cause and disease-specific mortality [7]. In a recent
epigenome-wide association study (EWAS) with ap-
proximately 1900 older adults followed up for 14 years
and an external validation with 1727 participants, we
identified 58 cytosine-phosphate-guanine (CpG) sites
within 19 chromosomes that were associated with
all-cause mortality [8]. We constructed a “mortality risk
score” (MS) based on the 10 most robustly
mortality-related loci, which was found to be a robust
and informative predictor of all-cause, CVD, and cancer
mortality. It is unclear, however, to what extent its asso-
ciation is independent of other well-established indica-
tors of mortality risks. This study aimed to explore
whether vitamin D status, defined by serum 25(OH)D
concentrations, is associated with the MS and to what
extent both indicators are individually and jointly cap-
able of predicting all-cause mortality in a general popu-
lation sample of older adults.
Methods
Study design and population
Study subjects were chosen from the ESTHER study, an
ongoing statewide population-based cohort study con-
ducted in Saarland, a state located in southwestern
Germany. Details of the study design have been reported
previously [8, 9]. As shown in Fig. 1, 9949 older adults
(aged 50–75 years) were enrolled by their general practi-
tioners during a routine health checkup between July
2000 and December 2002 and followed up thereafter.
The cross-sectional analysis of this study is based on the
data and biospecimen collected at baseline from 1467
participants (close to 100% Caucasian) who were
randomly selected for the measurements of 25(OH)D
concentrations and DNA methylation profiles among
participants recruited consecutively at the start of the
ESTHER study between July 2000 and March 2001 [10].
Participants were then regularly followed up with respect
to the incidence of major chronic diseases and mortality.
The ESTHER study was approved by the ethics commit-
tees of the University of Heidelberg and the state
medical board of Saarland, Germany. Written informed
consent was obtained from all participants.
Vitamin D measurements
Blood samples were taken during the health checkup
and stored at − 80 °C until further processing. As previ-
ously described [11], the automated Diasorin–Liaison
analyzer (Diasorin, Inc.) was used to measure total
serum 25(OH)D concentrations in women from baseline
serum samples in the central laboratory of the University
Clinic of Heidelberg in 2006 within the framework of a
project on women’s health. Additional funding was
obtained in 2009 to measure total serum 25(OH)D
concentrations in men as well. As the Diasorin–Liaison
method used for women was no longer available at that
time, the automated IDS-iSYS analyzer (Immunodiag-
nostic Systems, GmbH) was used instead. Both assays
with their within- and between-assay coefficients and
lower limits of detection have been comprehensively
described elsewhere [12, 13]. Both immunoassays were
Fig. 1 Overview of the sampling procedures of participants for analysis
Gao et al. Clinical Epigenetics  (2018) 10:84 Page 2 of 10
standardized retrospectively to measurements by liquid
chromatography-tandem mass spectrometry (LC-MS/
MS), the gold standard method [14], in a random
subsample of 97 males and 97 females as previously
described [12, 13]. Vitamin D status defined by total
serum 25(OH)D concentrations were classified into
three categories with the following criteria: deficiency,
< 30 nmol/L; insufficiency, 30 to < 50 nmol/L; and
sufficiency, ≥ 50 nmol/L.
DNA methylation data
DNA from whole blood samples was collected using a
salting out procedure [15]. DNA methylation profiles were
determined by the Illumina Human Methylation 450K
Beadchip (Illumina, San Diego, CA, USA). As previously
described [10], samples were analyzed following the man-
ufacturer’s instruction at the Genomics and Proteomics
Core Facility of the German Cancer Research Center,
Heidelberg, Germany. Illumina’s GenomeStudio® (version
2011.1; Illumina Inc.) was employed to extract DNA
methylation signals from the scanned arrays (Module
version 1.9.0; Illumina Inc.). The methylation level of a
specific CpG site was quantified as a β value ranging from
0 (no methylation) to 1 (full methylation). According to
the manufacturer’s protocol, no background correction
was done and data were normalized to internal controls
provided by the manufacturer. All controls were checked
for inconsistencies in each measured plate. Probes with a
detection p value > 0.05 were excluded from analysis.
Illumina normalization and preprocessing methods imple-
mented in Illumina’s GenomeStudio® were utilized.
As described by Zhang et al., 10 CpG sites (cg01612140,
cg05575921, cg06126421, cg08362785, cg10321156,
cg14975410, cg19572487, cg23665802, cg24704287, and
cg25983901) were selected from the whole epigenome
data to build the MS [8]. Values within the fourth quartile
of cg08362785 and first quartile of the other nine loci
were defined to reflect aberrant methylation for each CpG
site, and the ordinal MS was determined as the cumulative
number of aberrantly methylated CpG sites (0–10). The
participants were further classified into three risk levels:
low: MS = 0–1, moderate: MS = 2–5, and high: MS > 5.
Covariate and outcome assessment
Information on socio-demographic characteristics, lifestyle
factors, dietary habits, and health status at baseline was
obtained by standardized self-administered questionnaires
[16]. Participants were asked about their past and present
smoking behaviors and were then categorized into current,
former, and never smokers. Information on BMI and
systolic blood pressure was extracted from a standardized
form filled by the general practitioners during the health
checkups. Serum total cholesterol and C-reactive protein
(CRP) were measured with Backman Synchon LX and
turbudimetry, respectively [11]. Prevalent CVD at baseline
was defined by either physician-reported coronary heart
disease or a self-reported history of a major cardiovascular
event, such as myocardial infarction, stroke, pulmonary em-
bolism, or revascularization of coronary arteries. Prevalent
diabetes was defined by physician diagnosis or the use of
glucose-lowering drugs. Prevalent cancer [ICD-10 C00-C99
except non-melanoma skin cancer (C44)] was determined
by self-report or record linkage with data from the Saarland
Cancer Registry (in German) [17].
Deaths of follow-up until the end of 2015 were retrieved
by record linkage with population registries in Saarland.
Participants who moved out of Saarland were considered
as censored at the date last known to be alive. Information
on the causes of death was obtained from death certifi-
cates provided by local public health offices and was coded
with ICD-10 codes.
Statistical analysis
First, major socio-demographic characteristics, lifestyle
factors, and the MS at baseline of 1467 participants, over-
all and stratified by vitamin D status, were summarized by
descriptive statistics, and differences among subsets were
tested for statistical significance by Kruskal-Wallis test
(continuous variables) and chi-square test (categorical
variables).
We then examined the associations of vitamin D status
and MS (risk levels) with all-cause mortality using three
multivariate Cox regression models which increasingly
adjusted for potential covariates, including age (years), sex
(male/ female), smoking status (current/former/never
smoking), alcohol consumption (g/day), BMI class [kg/m2;
underweight (< 18.5, < 1% of the study population) or
normal weight (18.5 to < 25), overweight (25 to < 30),
obese (≥ 30)], physical activity [inactive (< 1 h of physical
activity/week), medium or high (≥ 2 h of light or ≥ 2 h of
vigorous physical activity/week), low (other)], the preva-
lence of CVD (yes/no), diabetes (yes/no) and cancer (yes/
no), systolic blood pressure (mmHg), CRP (mg/L), total
cholesterol (mg/dL), intake of vitamin supplements (yes/
no), fish consumption (≤ 1 time/week/> 1 time/week), and
the season of blood draw (spring: March–May; summer:
June–August; autumn: September–November; winter:
December–February). Leukocyte distribution estimated by
Houseman’s algorithm was additionally controlled for in
the models in which the MS was involved [18]. The
dose-response curves of continuous 25(OH)D concentra-
tions and ordinal MS with all-cause mortality were evalu-
ated by restricted cubic spline regression using the SAS
macro from Desquilbet et al. [19]. All models for
dose-response analyses were adjusted for the covariates
described above. The 25th, 50th, and 75th percentiles of
the MS and the 30, 50, and 70 nmol/L of serum 25(OH)D
concentrations were selected as knots for each marker,
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Table 1 Characteristics of the ESTHER study participants at baseline according to vitamin D status
Characteristics Total
population
Subsets based on vitamin D status
< 30 nmol/L/
deficiency
30 to < 50 nmol/L/
insufficiency
≥ 50 nmol/L/
sufficiency
p value
N 1467 223 (15.2%) 637 (43.4%) 607 (41.4%)
Age (years) 62.1 (6.51) 62.4 (6.91) 62.4 (6.43) 61.6 (6.42) 0.105
Sex (male) 663 (45.2%) 61 (27.4%) 216 (33.9%) 386 (63.6%) < 0.0001
Smoking status < 0.0001
Current smoker 271 (18.5%) 46 (20.6%) 117 (18.4%) 108 (17.8%)
Former smoker 488 (33.3%) 61 (27.4%) 172 (27.0%) 255 (42.0%)
Never smoker 708 (48.3%) 116 (52.0%) 348 (54.6%) 244 (40.2%)
Body mass index a 0.0006
Underweight or normal weight (< 25.0) 397 (27.1%) 64 (28.7%) 161 (25.3%) 172 (28.3%)
Overweight (25 to < 30) 677 (46.2%) 91 (40.8%) 278 (43.6%) 308 (50.7%)
Obese (≥ 30.0) 390 (26.6%) 68 (30.5%) 196 (30.8%) 126 (20.8%)
Alcohol consumption b < 0.0001
Abstainer 466 (31.8%) 92 (41.3%) 222 (34.9%) 152 (25.0%)
Low 797 (54.3%) 100 (44.8%) 319 (50.1%) 378 (62.3%)
Intermediate 78 (5.3%) 5 (2.2%) 29 (4.6%) 44 (7.3%)
High 20 (1.4%) 2 (0.9%) 13 (2.0%) 5 (0.8%)
Physical activity c < 0.0001
Inactive 293 (20.0%) 51 (22.9%) 150 (23.6%) 92 (15.2%)
Low 673 (45.9%) 114 (51.1%) 295 (46.3%) 264 (43.5%)
Medium or high 501 (34.2%) 58 (26.0%) 192 (30.1%) 251 (41.4%)
Prevalence of major diseases
Cardiovascular disease 309 (21.1%) 46 (20.6%) 126 (19.8%) 137 (22.6%) 0.476
Diabetes d 228 (15.5%) 41 (18.4%) 100 (15.7%) 87 (14.3%) 0.352
Cancer 87 (5.9%) 15 (6.7%) 40 (6.3%) 32 (5.3%) 0.649
Systolic blood pressure (mmHg) e 139.9 (19.79) 140.8 (21.01) 140.2 (19.69) 139.4 (19.46) 0.537
C-reactive protein (mg/L) f 3.7 (7.28) 3.4 (4.42) 3.6 (8.23) 3.9 (7.07) 0.979
Total cholesterol (mg/dL) g 183.5 (60.23) 179.2 (66.15) 178.1 (59.23) 190.7 (58.3) 0.0002
Intake of vitamin D supplements (yes) h 563 (38.4%) 83 (37.2%) 244 (38.3%) 236 (38.9%) 0.934
Fish consumption (> 1 time/week) i 925 (63.1%) 133 (59.6%) 403 (63.3%) 389 (64.1%) 0.740
Mortality risk score (risk levels) 0.872
0–1/low 602 (41.0%) 96 (43.1%) 263 (41.3%) 243 (40.0%)
2–5/moderate 670 (45.7%) 95 (42.6%) 292 (45.8%) 283 (46.6%)
> 5/high 195 (13.3%) 32 (14.3%) 82 (12.9%) 81 (13.3%)
Mean values (standard deviation) for continuous variables and n (%) for categorical variables. Differences among subgroups of vitamin D status were tested by
Kruskal-Wallis test (continuous variables) and chi-square test (categorical variables)
aData missing for three participants
bData missing for 106 participants. Categories are defined as follows: abstainer, low (women, 0 to < 20 g/day; men, 0 to < 40 g/day), intermediate (20 to < 40 g/
day and 40 to < 60 g/day, respectively), high (≥ 40 and ≥ 60 g/day, respectively)
cCategories are defined as follows: inactive (< 1 h of physical activity/week), medium or high (≥ 2 h of vigorous or ≥ 2 h of light physical activity/week), low (other)
dData missing for 16 participants
eData missing for 27 participants
fData missing for 30 participants
gData missing for two participants
hData missing for 62 participants
iData missing for 56 participants
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respectively. In addition to models including either
vitamin D status or MS (risk levels) as the predictor, we
further evaluated their independent associations with
all-cause mortality in a model containing both predictors.
Finally, we assessed the joint associations of both indica-
tors with all-cause mortality. Survival was first compared
by the health status defined by the combination of both
indicators using direct-adjusted survival curves (adjusted
for age and sex), followed by Cox regression analyses with
multivariable adjustment. In addition, adjusted survival
curves were constructed and Cox models were run to
assess the associations of MS with mortality within
subgroups of participants defined by vitamin D status and
of vitamin D status with mortality within subgroups of
participants defined by the MS (risk levels). To avoid
overadjustment, only covariates related to either of the
two predictors (p value < 0.2 in bivariable analyses) were
included in the models assessing joint associations.
All analyses were performed by SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA). For all statistical analyses,
a p value less than 0.05 in two-sided tests was consid-
ered as statistically significant.
Results
Participant characteristics
Characteristics of all 1467 participants and the subsets
based on vitamin D status are shown in Table 1. For the
total population, the average age was about 62 years. More
than half of the participants were smokers (current or
former smokers). The majority of participants were over-
weight or obese, reported no or low amounts of alcohol
consumption, and no or only low physical activity. More
than half of the participants had a MS > 1, and about 46%
had a MS of 2–5. The mean standardized serum 25(OH)D
concentration was 52.1 nmol/L, with 15.2 and 43.4% of
participants meeting the criteria for vitamin D deficiency
(< 30 nmol/L) and insufficiency (30 to < 50 nmol/L), re-
spectively. During a median follow-up time of 15.2 years,
365 (24.9%), 128 (8.9%), and 134 (9.3%) participants died
from any cause, CVD, or cancer, respectively.
Participants with sufficient vitamin D (≥ 50 nmol/L) in-
cluded larger proportions of males, former smokers,
consumers of low amounts of alcohol, were less often
obese and more often reported medium or high physical
activity than those with vitamin D deficiency and insuffi-
ciency. By contrast, no differences in the prevalence of
major diseases and in the distribution of the MS were
observed among participants with vitamin D deficiency,
insufficiency, or sufficiency.
Individual associations of vitamin D status and the
mortality risk score with all-cause mortality
Table 2 shows the associations of vitamin D status and
MS (risk levels) with all-cause mortality among 1467
participant during a median follow-up time of 15.2 years.
Significant associations were observed between each
indicator and mortality, which persisted after controlling
for multiple covariates. Vitamin D insufficiency and
deficiency were associated with about 1.5- [hazard ratio
(HR) 1.46; 95% CI 1.11–1.93] and 2.0 (HR 1.99; 95% CI
1.38–2.87)-fold mortality compared to the vitamin D
sufficiency subgroup after adjustment of multiple covari-
ates (model 3). The moderate and high MS risk levels
were associated with about 1.9- (HR 1.87; 95% CI 1.37–
2.54) and 3.4 (HR 3.42; 95% CI 2.32–5.04)-fold mortality
compared to the low MS risk level. Additional mutual
adjustment for both indicators did not alter the patterns
in any relevant manner with essentially unchanged HRs.
Figure 2 further depicts the dose-response relation-
ships of 25(OH)D concentrations and ordinal MS with
Table 2 Associations of vitamin D status and mortality risk score (risk levels) with all-cause mortality
Characteristics N total N death Model 1
a Model 2 b Model 3 c Model with both indicators d
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Vitamin D status
≥ 50 nmol/L /sufficiency 607 138 Reference Reference Reference Reference
30 to < 50 nmol/L/
insufficiency
637 156 1.31 (1.03–1.67) 0.027 1.30 (1.01–1.69) 0.045 1.46 (1.11–1.93) 0.008 1.43 (1.08–1.88) 0.013
< 30 nmol/L/deficiency 223 71 2.03 (1.48–2.79) < 0.0001 1.95 (1.39–2.74) 0.0001 1.99 (1.38–2.87) 0.0003 2.08 (1.44–3.01) < 0.0001
Mortality risk score (risk levels)
0–1/low 602 86 Reference Reference Reference Reference
2–5/moderate 670 180 1.85 (1.42–2.41) < 0.0001 1.76 (1.33–2.33) < 0.0001 1.87 (1.37–2.54) < 0.0001 1.89 (1.39–2.57) < 0.0001
> 5/high 195 99 4.13 (3.04–5.62) < 0.0001 2.99 (2.11–4.24) < 0.0001 3.42 (2.32–5.04) < 0.0001 3.38 (2.30–4.96) < 0.0001
HR hazard ratio, CI confidence interval
aAdjusted for age, sex, and the season of blood draw; the leukocyte distribution (Houseman algorithm) was additionally adjusted for the models with
mortality risk score
bAdditionally adjusted for alcohol consumption, smoking status, BMI class, physical activity, regular intake of vitamin supplements, and
fish consumption
cAdditionally adjusted for the prevalence of CVD, diabetes and cancer, systolic blood pressure, CRP, and total cholesterol
dAdjusted for the covariates added in model 3
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all-cause mortality after controlling for all potential
covariates. Mortality strongly increased for 25(OH)D
concentrations < 40 nmol/L and steadily increased with
increasing MS.
Joint associations of vitamin D status and mortality risk
score with all-cause mortality
Figure 3 presents the direct-adjusted survival curves for
the joint association of vitamin D status and the MS (risk
levels) with all-cause mortality during a median follow-up
time of 15.2 years. People in the highest risk group with
vitamin D deficiency and high MS risk level had a substan-
tially higher overall death rate than all other groups. After
adjustment for the selected covariates based on the results
of bivariate associations (Additional file 1: Table S1), a
clearly increasing mortality risk (i.e., HR) was observed with
both vitamin D deficiency and a high MS (Table 3). In
particular, people in the highest risk group of both factors
had about 5.8-fold mortality compared to the people in the
reference group that had sufficient vitamin D and a low MS
(HR 5.79; 95% CI 3.06–10.94).
We further stratified the total population by each indica-
tor and assessed the association of the other indicator with
all-cause mortality. As demonstrated in Tables 4 and 5 and
Additional file 2: Figure S1, the identified patterns in
subgroup-specific analyses are in line with the findings for
the total study population. However, the association of a
high MS with all-cause mortality was particularly strong
a
b
Fig. 2 Graphs of the best-fitting models for relationships of 25(OH)D concentrations (a) and the ordinal mortality risk score (b) with all-cause
mortality. Legend: red lines, estimation; dashed lines, confidence limits; red dots, knots; green lines, reference lines
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among participants with vitamin D deficiency (HR 6.90;
95% CI 2.83–16.83). Additional sex-specific analysis yielded
similar patterns for both sexes (data not shown).
Discussion
In this study with 1467 older adults recruited in a
population-based cohort with both measurements of serum
25(OH)D concentrations and DNA methylation profiles at
baseline, vitamin D status and an epigenetic-based MS
strongly and independently predicted mortality from any
causes. In particular, the combination of both indicators
demonstrated the potential to be a robust prognostic
marker for all-cause mortality with an approximately
sixfold mortality among those with vitamin D deficiency
and a high MS compared to participants with sufficient
vitamin D and a low MS.
Previous studies suggested that there might be a recipro-
cal relationship between vitamin D and epigenetic changes:
epigenetic alterations regulate the expression of vitamin D
receptor genes and vitamin D could influence epigenetic
events [20]. Previous studies have also suggested epigenetic
effects of vitamin D on histone modification, another form
of epigenetic regulation [20, 21]. Although a potential link
between severe vitamin D deficiency and DNA methylation
has been reported in African American adolescents [22], no
such link was observed in a previous analysis of the
ESTHER study [23]. In addition, Chavez et al. using the
Illumina 450K array did not find significant alterations in
DNA methylation profiles when they exposed human blood
cells to vitamin D for up to 120 h [24]. In our study, vita-
min D deficiency was not related to the methylation of the
sites included in the MS. Among the 10 CpG sites of the
MS, four loci are smoking-related, including cg05575921
(AHRR), cg06126421 (6p21.33), cg19572487 (RARA), and
cg01612140 (6q14.1) [25]. Even though vitamin D suffi-
ciency may have a protective effect against the damaging ef-
fects of smoking on lung function [26], we did not observe
any association of the MS and vitamin D status. Along the
same lines, although loci cg08362785 and cg23665802 are
mapped to genes MKL1 and MIR19A that are associated
with the risks of lung and breast cancer [27, 28], vitamin D,
which was found to be related to the incidence and mortal-
ity of both cancers [29], did not show any relation with
either locus nor the MS.
Associations between both vitamin D deficiency and the
MS, and all-cause mortality have been identified and vali-
dated by previous studies among older adults [3, 7, 8, 30].
To our best knowledge, this study is the first investigation
which further demonstrated that both markers are not
only capable of independently predicting the death from
any cause over 15 years of follow-up, but also can be inte-
grated together to be an extraordinarily strong indicator
for mortality.
In particular, the combination of vitamin D and the MS
appears to be a better predictor of all-cause mortality than
any previously suggested biomarkers of mortality risk [31].
The strength of the association is the more remarkable, as
Fig. 3 Age- and sex-adjusted survival curves for the joint associations
of vitamin D status and mortality risk score (risk levels) with all-cause
mortality (log-rank p value < 0.0001). Legend: Each curve represents
the subgroup defined by the combination of vitamin D status and
mortality risk score (risk levels)
Table 3 Joint associations of vitamin D status and mortality risk score (risk levels) with all-cause mortality: joint association using
people with sufficient vitamin D and low mortality risk score as reference group
Characteristics Mortality risk score (risk levels)
0–1/low 2–5/moderate > 5/high
Death/total HR (95% CI) p value Death/total HR (95% CI) p value Death/total HR (95% CI) p value
Vitamin D status (category)
≥ 50 nmol/L/sufficiency 34/243 Reference 65/283 1.28 (0.81–2.03) 0.292 39/81 2.50 (1.48–4.22) 0.0006
30 to < 50 nmol/L/
insufficiency
34/263 0.96 (0.56–1.65) 0.894 83/292 2.21 (1.41–3.45) 0.0005 39/82 3.34 (1.94–5.75) < 0.0001
< 30 nmol/L/deficiency 18/96 1.50 (0.79–2.86) 0.214 32/95 2.86 (1.65–4.97) 0.0002 21/32 5.79 (3.06–10.94) < 0.0001
HR hazard ratio, CI confidence interval
After the selection of covariates based on bivariate associations, models are adjusted for age, sex, BMI class, smoking status, physical activity, alcohol
consumption, CRP, total cholesterol, the prevalence of cardiovascular disease and diabetes, season of blood draw, and the selected leukocyte distribution
(Houseman algorithm, including CD4+ T cells, CD8+ T cells, B cells, and granulocytes)
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most of the deaths in our study with long-term follow-up
occurred many years after baseline measurements of
vitamin D and MS, whereas the strength of prediction for
most biomarkers is typically attenuated with increasing
length of follow-up [32, 33]. Even stronger associations of
both biomarkers and their combinations with mortality
were seen when the follow-up was restricted to 5 or
10 years, even though confidence intervals became wider
due to the lower numbers of deaths (data not shown).
One of the major strengths of this study is the
availability of a broad range of covariates adjusted for in
addition to epigenome-wide methylation data in a
population-based cohort that was comprehensively
followed up with high completeness over 15 years. We
also acknowledge several limitations in the interpretation
of results. First, the overall number of deaths for the
survival analyses was limited, which caused rather wide
confidence intervals for some of the HR estimates.
Furthermore, shifts of leukocyte distribution might affect
the associations of DNA methylation in whole blood
samples [34]. Hence, we adjusted for leukocyte distribu-
tion by the Houseman algorithm to restrict potential
confounding from differential blood counts to the
greatest possible extent [18]. In addition, 25(OH)D
concentrations were originally measured by two different
methods. Nevertheless, standardization by the gold
standard LC-MS/MS method, which yielded results that
were highly correlated with original measurements [13],
should ensure comparability and validity of the vitamin
D status included in our analysis. Finally, due to the
heterogeneity of populations with respect to food fortifi-
cation, use of dietary supplements, UV radiation levels,
and susceptibility of the epigenome in response to exter-
nal exposure, further studies are needed to evaluate to
Table 4 Joint associations of vitamin D status and mortality risk score (risk levels) with all-cause mortality: associations of mortality
risk score with all-cause mortality within subgroups defined by vitamin D status
Characteristics Mortality risk score (risk levels)
0–1/low 2–5/moderate > 5/high
Death/total HR (95% CI) p value Death/total HR (95% CI) p value Death/total HR (95% CI) p value
Vitamin D status (category)
Overall 86/602 Reference 180/670 1.77 (1.32–2.36) 0.0001 99/195 3.24 (2.24–4.68) < 0.0001
≥ 50 nmol/L/sufficiency 34/243 Reference 65/283 1.18 (0.73–1.91) 0.504 39/81 2.44 (1.34–4.43) 0.003
30 to < 50 nmol/L/insufficiency 34/263 Reference 83/292 2.62 (1.65–4.15) <
0.0001
39/82 4.37 (2.37–8.05) < 0.0001
< 30 nmol/L/deficiency 18/96 Reference 32/95 2.21 (1.11–4.38) 0.024 21/32 6.90 (2.83–16.83) < 0.0001
HR hazard ratio, CI confidence interval
After the selection of covariates based on bivariate associations, models are adjusted for age, sex, BMI class, smoking status, physical activity, alcohol
consumption, CRP, total cholesterol, the prevalence of cardiovascular disease and diabetes, season of blood draw, and the selected leukocyte distribution
(Houseman algorithm, including CD4+ T cells, CD8+ T cells, B cells, and granulocytes)
Table 5 Joint associations of vitamin D status and mortality risk score (risk levels) with all-cause mortality: associations of vitamin D
status with all-cause mortality within subgroups defined by mortality risk score
Characteristics Mortality risk score (risk levels)
Overall 0–1/low 2–5/moderate > 5/high
Death/
total
HR (95% CI) p value Death/
total
HR (95% CI) p value Death/
total
HR (95% CI) p value Death/
total
HR (95% CI) p value
Vitamin D status
(category)
≥ 50 nmol/L/
sufficiency
138/607 Reference 34/243 Reference 65/283 Reference 39/81 Reference
30 to <
50 nmol/L/
insufficiency
156/637 1.43
(1.10–1.86)
0.007 34/263 0.91
(0.51–1.64)
0.758 83/292 1.69
(1.16–2.48)
0.007 39/82 1.30
(0.79–2.17)
0.295
< 30 nmol/L/
deficiency
71/223 2.01
(1.41–2.85)
< 0.0001 18/96 1.64
(0.78–3.45)
0.193 32/95 2.16
(1.30–3.60)
0.003 21/32 1.97
(1.01–3.84)
0.047
HR hazard ratio, CI confidence interval
After the selection of covariates based on bivariate associations, models are adjusted for age, sex, BMI class, smoking status, physical activity, alcohol
consumption, CRP, total cholesterol, the prevalence of cardiovascular disease and diabetes, season of blood draw, and the selected leukocyte distribution
(Houseman algorithm, including CD4+ T cells, CD8+ T cells, B cells, and granulocytes)
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what extent our findings can be generalized to other
populations: in particular younger individuals and
non-Caucasians.
Conclusions
In summary, our results contribute to a rapidly growing
body of literature investigating the prediction of age-related
morbidity and long-term mortality by various markers
identified from environmental, genetic, and epigenetic re-
search. We showed that the application of both vitamin D
status and the MS based on DNA methylation signatures
yielded a robust, independent predictor for all-cause mor-
tality, suggesting that vitamin D status and DNA methyla-
tion signatures in combination may be most useful in risk
stratification as potential intermediate biomarkers. Further
studies are warranted to elucidate the underlying patho-
physiological mechanisms and potential clinical applica-
tions of the combination of both indicators in routine
medical practice and intervention research aimed at redu-
cing mortality.
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